Limited sampling strategy for cyclosporine (Neoral®) area under the curve monitoring in pediatric kidney transplant recipients
Authors:
- 3 September 2005
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 9 (5) , 566-573
Abstract
Cyclosporine (CSA; Neoral) is one of the most common immunosuppressants used in pediatric renal transplantation. Research in adult renal transplant recipients has shown that 2-h post-dose concentration (C2) monitoring and limited sampling strategies (LSSs) are better at predicting drug exposure and outcome than trough concentrations (C0). While C0 monitoring is the usual practice in pediatric renal transplant patients, area under the curve (AUC) monitoring has been shown to be superior in terms of predictive ability and outcomes. However, AUC monitoring is impractical and inconvenient in a clinic setting because it involves many blood samples. An LSS provides a reliable alternative. The purpose of this study was to prospectively define an LSS (AUC(0-12)) for CSA monitoring and to test its predictive performance. As well, an LSS (AUC(0-4)) for CSA was developed and its predictive performance tested. Blood samples for CSA concentrations were collected in 29 stable pediatric renal transplant patients prior to (t = 0) and at 0.5, 1, 2, 4, 6, and 8 h following a steady-state morning CSA dose. AUC was calculated by the trapezoidal method; LSSs for AUC(0-12) and AUC(0-4) were determined using multiple regression analysis in 14 patients; and the LSSs' predictive performance was tested in 15 additional patients. Both LSSs require two blood samples. For the LSS (AUC(0-12)), blood samples are required immediately before the dose and 2 h post-dose: AUC(0-12) = 12.45 C0 + 2.17 C2 + 723.16 (r2 = 0.909). For the LSS (AUC(0-4)), blood samples are required at one and 2 h post-dose, AUC(0-4) = 1.17 C1 + 1.85 C2 - 41.00 (r2 = 0.971). The LSSs demonstrated low bias and high precision for both AUC(0-12) and AUC(0-4). Our two-concentration LSSs are accurate and precise predictors that are more clinically useful for our patient population than other LSSs that have been developed for pediatric renal transplant patients. Our study template provides a guide for other centers to develop accurate and precise LSSs specific to their own patient population.Keywords
This publication has 41 references indexed in Scilit:
- C2 monitoring: a reliable tool in pediatric renal transplant recipientsTransplantation, 2003
- Two-Hour Cyclosporine Concentration Determination: An Appropriate Tool to Monitor Neoral Therapy?Therapeutic Drug Monitoring, 2002
- Immunosuppressive Therapy for Paediatric Transplant PatientsClinical Pharmacokinetics, 2002
- Methods for Clinical Monitoring of Cyclosporin in Transplant PatientsClinical Pharmacokinetics, 2000
- NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVETransplantation, 1999
- Abbreviated cyclosporine AUCs on Neoral - the search continues!Pediatric Nephrology, 1999
- Cyclosporine A monitoring in children: abbreviated area under curve formulas and C2 levelPediatric Nephrology, 1999
- Cyclosporin Pharmacokinetics in Paediatric Transplant RecipientsClinical Pharmacokinetics, 1997
- Within-Day Consistency in Cyclosporine Pharmacokinetics from a Microemulsion Formulation in Renal Transplant PatientsTherapeutic Drug Monitoring, 1994
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981